SBI Holdings, Inc. (SBHGF) Q1 2027 Earnings Call Prepared Remarks Transcript

SBI Holdings reported Q1 2027 revenue of JPY 571B and profit before tax of JPY 225.8B, with profit attributable to owners at JPY 148.1B—record highs across line items. Pretax profit rose 149.9% YoY (+59.5% noted for pretax profit vs prior period context) and ROE annualized reached 29% vs ~15% in the midterm plan, driven mainly by Financial Services amid a robust equity market. Management flagged weakness in the crypto asset business due to the anticipated CLARITY Act, but broader segments (asset management/PE/nextgen) posted revenue and pretax profit records alongside continued investments including M&A and funding.

Analysis

SBI’s print matters less as a standalone beat than as evidence that Japanese financials with fee/market-sensitive mix are getting leverage from the same equity regime that is pressuring slower-moving universal brokers. The relative message is strongest versus NMR: when capital markets are active, the market tends to pay up for cleaner ROE delivery, and a 29% annualized return profile creates a sharp contrast with lower-growth, more legacy-sensitive platforms. If this persists for another 1-2 quarters, expect the valuation spread between high-turnover, digitally distributed financials and branch-heavy brokers to widen further.

The crypto weakness is the key nuance, but it is more of a timing issue than a thesis breaker. Near term, regulatory anticipation can suppress transaction activity and delay balance-sheet commitment; over 6-18 months, the same clarity can lower compliance friction and reopen institutional adoption, which makes the segment an embedded call option rather than a core valuation driver. The bigger second-order effect is that SBI’s capital allocation engine appears strong enough to keep funding PE/M&A and adjacent financial products, siphoning deal flow from incumbents that rely on a narrower securities franchise.

Main risk: this is still a beta-rich earnings story. If Japanese equities stall or volatility rises, the earnings mix can normalize quickly and the ROE headline will compress first. The catalyst path to watch over the next 1-3 months is whether management converts the current print into higher guidance, buybacks, or explicit capital return; if not, the market may treat this as a cyclical peak rather than a structural step-up. Falsify the thesis if the next quarter shows weaker market-driven fees or if crypto/regulatory drag starts offsetting core profitability again.

Key Decisions for Investors

• Long SBHGF / short NMR as a 1-3 month relative-value pair: thesis is continued ROE and fee-income divergence while Japanese equity markets stay constructive. Target a 10-15% spread if SBI maintains operating leverage; cut if TOPIX rolls over or NMR closes the profitability gap through guidance improvement.
• Accumulate SBHGF on any post-earnings consolidation rather than chasing the gap move. The immediate reaction may already reflect the beat; the better entry is a pullback that still holds above the pre-earnings breakout level, with a 6-18 month view tied to capital return and ROE durability.
• Use SBHGF as a watchlist long into the next quarterly update only if management reiterates elevated ROE and does not flag deterioration in the crypto segment. If ROE falls back below ~20% annualized or market-linked profits mean-revert, the re-rating case weakens materially.
• Do not short NMR outright on this headline alone; prefer the pair trade. NMR is more exposed to a market beta recovery, so an outright short risks getting squeezed if Japanese risk assets remain firm even as SBI continues to outperform on execution.